193 related articles for article (PubMed ID: 36495581)
21. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.
Mahal BA; Chen YW; Muralidhar V; Mahal AR; Choueiri TK; Hoffman KE; Hu JC; Sweeney CJ; Yu JB; Feng FY; Kim SP; Beard CJ; Martin NE; Trinh QD; Nguyen PL
Ann Oncol; 2017 May; 28(5):1098-1104. PubMed ID: 28453693
[TBL] [Abstract][Full Text] [Related]
22. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
23. Decrease in Prostate Cancer Testing Following the US Preventive Services Task Force (USPSTF) Recommendations.
Li J; Berkowitz Z; Hall IJ
J Am Board Fam Med; 2015; 28(4):491-3. PubMed ID: 26152440
[TBL] [Abstract][Full Text] [Related]
24. Changes in Prostate-specific Antigen Screening after the 2018 United States Preventive Services Task Force Recommendations and Through the COVID-19 Pandemic.
Qian Z; Chen X; Cole AP; Abdollah F; Choueiri TK; Kibel AS; Lipsitz SR; Iyer HS; Trinh QD
Eur Urol Oncol; 2024 Feb; 7(1):151-154. PubMed ID: 37487814
[TBL] [Abstract][Full Text] [Related]
25. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.
Kelly SP; Anderson WF; Rosenberg PS; Cook MB
Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421
[TBL] [Abstract][Full Text] [Related]
26. Abrogation of survival disparity between Black and White individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation.
Kim IE; Jang TL; Kim S; Modi PK; Singer EA; Elsamra SE; Kim IY
Cancer; 2020 Dec; 126(23):5114-5123. PubMed ID: 32888321
[TBL] [Abstract][Full Text] [Related]
27. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
[TBL] [Abstract][Full Text] [Related]
28. Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.
Schröder FH; Roobol-Bouts M; Vis AN; van der Kwast T; Kranse R
Urology; 2001 Jan; 57(1):83-90. PubMed ID: 11164149
[TBL] [Abstract][Full Text] [Related]
29. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.
Drazer MW; Huo D; Eggener SE
J Clin Oncol; 2015 Aug; 33(22):2416-23. PubMed ID: 26056181
[TBL] [Abstract][Full Text] [Related]
30. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
31. The role of the digital rectal examination as diagnostic test for prostate cancer detection in obese patients.
Dell'Atti L
J BUON; 2015; 20(6):1601-5. PubMed ID: 26854458
[TBL] [Abstract][Full Text] [Related]
32. The impact of different prostate-specific antigen (PSA) testing intervals on Gleason score at diagnosis and the risk of experiencing false-positive biopsy recommendations: a population-based cohort study.
Palsdottir T; Nordstrom T; Karlsson A; Grönberg H; Clements M; Eklund M
BMJ Open; 2019 Mar; 9(3):e027958. PubMed ID: 30928965
[TBL] [Abstract][Full Text] [Related]
33. Prospective study of cancer detection in black and white men with normal digital rectal examination but prostate specific antigen equal or greater than 4.0 ng/mL.
Fowler JE; Bigler SA; Farabaugh PB
Cancer; 2002 Mar; 94(6):1661-7. PubMed ID: 11920526
[TBL] [Abstract][Full Text] [Related]
34. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
35. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
[TBL] [Abstract][Full Text] [Related]
36. Similar perspectives on prostate cancer screening value and new guidelines across patient demographic and PSA level subgroups: A qualitative study.
Partin MR; Lillie SE; White KM; Wilt TJ; Chrouser KL; Taylor BC; Burgess DJ
Health Expect; 2017 Aug; 20(4):779-787. PubMed ID: 27807905
[TBL] [Abstract][Full Text] [Related]
37. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.
Thompson IM; Ankerst DP; Chi C; Lucia MS; Goodman PJ; Crowley JJ; Parnes HL; Coltman CA
JAMA; 2005 Jul; 294(1):66-70. PubMed ID: 15998892
[TBL] [Abstract][Full Text] [Related]
38. Decline in Prostate Cancer Screening by Primary Care Physicians: An Analysis of Trends in the Use of Digital Rectal Examination and Prostate Specific Antigen Testing.
Shoag J; Halpern JA; Lee DJ; Mittal S; Ballman KV; Barbieri CE; Hu JC
J Urol; 2016 Oct; 196(4):1047-52. PubMed ID: 27060052
[TBL] [Abstract][Full Text] [Related]
39. Diagnosis of isolated high-grade prostatic intra-epithelial neoplasia: proposal of a nomogram for the prediction of cancer detection at saturation re-biopsy.
Roscigno M; Scattoni V; Freschi M; Abdollah F; Maccagnano C; Galosi A; Lacetera V; Montironi R; Muzzonigro G; Deho F; Deiana G; Belussi D; Chinaglia D; Montorsi F; Da Pozzo LF
BJU Int; 2012 May; 109(9):1329-34. PubMed ID: 21895935
[TBL] [Abstract][Full Text] [Related]
40. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
Vickers AJ; Till C; Tangen CM; Lilja H; Thompson IM
J Natl Cancer Inst; 2011 Mar; 103(6):462-9. PubMed ID: 21350221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]